Physician profile
Codi D Ehrlich
NPI 1316442130
$2,516.15
in general payments reported to CMS, 2019-2025
21 companies · $645 in 2025
The $645 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $239 · 2023: $821 · 2024: $812 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $617.79 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $400.89 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $348.56 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $241.78 | 2023-2025 | |
| Pfizer INC. | $180.66 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $111.85 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $88.35 | 2022-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Abbott Laboratories | $78.19 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $76.52 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Exact Sciences Corporation | $72.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Grifols USA, LLC | $66.57 | 2024 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $45.37 | 2022-2025 | Penmenvy, Bexsero, Shingrix |
| Novartis Pharmaceuticals Corporation | $34.42 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.56 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $20.01 | 2025 | Fluad, Flucelvax |
| Medtronic, INC. | $17.86 | 2025 | Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.61 | 2023 | Jardiance |
| Amgen INC. | $15.81 | 2025 | Evenity |
| Phathom Pharmaceuticals, INC. | $13.73 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Codi Ehrlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.